Siemens Healthineers is set to unveil a new SPECT/CT system, Symbia Intevo Bold, at next week's annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
The hybrid scanner, which has received clearance from the U.S. Food and Drug Administration (FDA), is designed for a range of clinical applications in a dual-use setting much like PET/CT. It features as an option the company's sinogram-affirmed iterative reconstruction (SAFIRE) algorithm for enhanced CT image quality and image reconstruction, which can reduce patient radiation dose by as much as 60%, according to the company.
Also available on Symbia Intevo Bold is an iterative metal artifact reduction (iMAR) algorithm designed to reduce artifacts caused by metallic materials such as orthopedic and dental implants. In addition, a feature called optional interleaved volume reconstruction (IVR) reconstructs overlapping CT images up to 32 slices to extract the maximum amount of diagnostic information from measured data, enabling evaluation of small structures such as lesions or fractures.
Symbia Intevo Bold also offers as an option xSPECT Quant quantification technology for automated, reproducible quantification of technetium-99m, iodine-123, lutetium-177, and indium-111. xSPECT Quant is not yet commercially available in all countries.
In other news, Siemens reported that it has received FDA clearance for its syngo.via VB20 for molecular imaging software, which offers new features and improvements designed for enhanced workflows and use with PET and SPECT. The software's new multifoci segmentation (MFS) feature for PET and SPECT is designed for automatic, one-click calculation of a patient's whole-body tumor burden.
In addition, the OncoBoard feature of syngo.via VB20 for molecular imaging displays pretherapy and post-therapy treatment responses simultaneously to better evaluate disease progression and advance patient care.
